Expert recommendation on diagnostic-therapeutic management in skin carcinomas

Rutkowski, Piotr; Owczarek, Witold; Nejc, Dariusz; Jeziorski, Arkadiusz; Wysocki, Wojciech M.; Słowińska, Monika; Dudzisz-Śledź, Monika; Wiśniewski, Piotr; Tchórzewska-Korba, Hanna; Szumera‐Ciećkiewicz, Anna; Koseła-Paterczyk, Hanna; Kiprian, Dorota; Świtaj, Tomasz; Królicki, Leszek; Murawa, Dawid; Zdziniecki, Marcin; Ziętek, Marcin; Maciejczyk, Adam; Rudnicka, Lidia

doi:10.5603/ocp.2021.0032

Cited by 4 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At the same time, MCSs are poorly differentiated tumors sensitive to RT and chemotherapy [ 96 ]. Given the relatively small number of patients with CSs, it is recommended to refer MSC patients to reference sarcoma centers [ 93 , 94 , 97 ]. In our study by Rutkowski et al, 10-year OS decreased to 17% in patients who could not undergo radical excision [ 96 ].…”

Section: Treatment Of Locally Advanced Diseasementioning

confidence: 99%

“…The consensus of sarcoma experts is to use Ewing sarcoma–like treatment regimens in MSC, although no randomized trial has been performed to confirm this approach [ 103 ]. MSC systemic treatment therefore generally includes alternating cycles of etoposide plus ifosfamide (EI) and adriamycin with vincristine and cyclophosphamide (CAV) [ 93 ].…”

Section: Treatment Of Locally Advanced Diseasementioning

confidence: 99%

See 1 more Smart Citation

Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials

Dudzisz-Śledź,

Kondracka,

Rudzińska

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Mesenchymal chondrosarcoma (MCS) is a rare subtype of chondrosarcoma with a poor prognosis. Although these tumors are sensitive to radiotherapy/chemotherapy, the standard treatment for localized MCS is only surgical resection, and there are no established treatment guidelines for patients with advanced and metastatic MCS. Due to the low incidence of MCS, the pathology of these tumors is still unknown, and other therapeutic options are lacking. Some studies show the potential role of the PDGF/PPI3K/AKT, PKC/RAF/MEK/ERK, and pRB pathways, and BCL2 overexpression in the pathogenesis of MCS. These findings provide an opportunity to use protein kinases and BCL2 inhibitors as potential therapy in MCS. In this review, we summarize the current knowledge about MCS diagnosis and treatment options. We show the immunological and molecular biomarkers used in the diagnosis of MCS. In addition, we discuss the known prognostic and predictive factors in MCS. Finally, we present the novel trends, including targeted therapies and ongoing clinical trials using protein kinase inhibitors and the death receptor 5 (DR5) agonist, which may be the focus of future MCS treatment studies.

show abstract

Section: Treatment Of Locally Advanced Diseasementioning

confidence: 99%

Section: Treatment Of Locally Advanced Diseasementioning

confidence: 99%

Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials

Dudzisz-Śledź,

Kondracka,

Rudzińska

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although the majority of patients with skin cancer are diagnosed in the early stage of the disease and are cured surgically, still there is a significant number of patients worldwide at stage III-IV disease, for whom other treatment modalities may be necessary. Recent developments and approval of targeted agents and immunotherapy have significantly changed the landscape of the therapy of cutaneous malignancies in the metastatic setting, and they have recently translated into progress in neo-/adjuvant treatment in high-risk locoregional disease [1][2][3][4][5].…”

Section: Piotr Rutkowskimentioning

confidence: 99%

“…The survival of advanced melanoma and skin carcinoma patients has greatly improved within the last few years. This unprecedented development is mainly related to the introduction of 2 different therapeutic strategies: immunotherapy with use of immune checkpoint inhibitors anti-CTLA4 and/or anti-PD1 in melanoma, SCC, and Merkel cell carcinoma, as well as targeted therapy with kinase inhibitors for BRAF and MEK and hedgehog inhibitors in melanoma and BCC, respectively [1][2][3][4][5]. Table I summarizes all new systemic therapies available for advanced cutaneous malignancies.…”

Section: Piotr Rutkowskimentioning

confidence: 99%

“…The prognosis of patients with melanoma at stage IIB-IV after a complete resection of the lesions is highly heterogenous and related to disease recurrences in 30-70% of cases. Currently, systemic adjuvant treatment with immunotherapy (nivolumab and pembrolizumab) and targeted therapy (dabrafenib and trametinib in BRAF-mutated cases) after surgery in high-risk patients is the standard treatment administered postoperatively with curative intent, leading to decreasing disease relapses at approximately 20% after long-term follow-up [1][2][3][4][5]. New data from 2022 indicate that also the use of adjuvant therapy in earlier stages (IIB-IIC) in high-risk melanomas without nodal metastases statistically significantly improves relapse-free survival (RFS).…”

Section: Piotr Rutkowskimentioning

confidence: 99%

See 1 more Smart Citation

The greatest achievements in oncology in 2022 – melanoma and skin carcinomas

Rutkowski

2022

Arch Med Sci

Self Cite

View full text Add to dashboard Cite

Skin cancer diagnosis using the deep learning advancements: a technical review

Pandey,

Shankhdhar

2024

Bulletin EEI

View full text Add to dashboard Cite

It is vital in today's technologically advanced society to combat skin cancer using machines rather than human intervention. Any time the look of the skin changes abnormally, there is a danger that the person might be at risk for skin cancer. Dermatology expertise and computer vision methods must be merged to diagnose melanoma more effectively. Because of this, it is necessary to learn about numerous detection methods to help doctors discover skin cancer at an early stage. This research paper provides a comprehensive technical review of the advancements in using deep learning techniques for the diagnosis of skin cancer. Since skin cancer is so prevalent, early identification is essential for better treatment results. Among the medical uses where deep learning, a kind of machine learning, has shown promise is in the identification of skin cancer. This research investigates the most cutting-edge skin cancer diagnostic deep-learning approaches, datasets, and assessment metrics currently in use. This study discusses the benefits and drawbacks of using deep learning for skin cancer detection. Challenges include ethical and privacy considerations about patient data, the incorporation of models into clinical procedures, and problems with dataset bias and generalisation.

show abstract

Expert recommendation on diagnostic-therapeutic management in skin carcinomas

Cited by 4 publications

References 0 publications

Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials

Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials

The greatest achievements in oncology in 2022 – melanoma and skin carcinomas

Skin cancer diagnosis using the deep learning advancements: a technical review

Contact Info

Product

Resources

About